TGFB1 and neoplasm: Use of the anti-Nrp-1 antibody resulted in a significantly augmented number of CD4+TGF-β1+ Th3 cells in the TDLN and tumor tissue (Supplementary Fig. S3A,B) and tumor-derived TGF-β1-producing Treg cells (Supplementary Fig. S3C) from IL10−/− B16/F10 and WT B16/F10 mice.